Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE Most BRCA1 carriers (73%) had triple-negative breast cancer; whereas most BRCA2 carriers (72%) had hormone receptor-positive tumors. 31581314 2020
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE Two distinct BRCA2 pathogenic variants c.1813dupA and c.8485C > T detected in two young female triple negative breast cancer (TNBC) patients, respectively, with a family history of male breast cancer, are reported here for the first time in Algerian population. 30715675 2019
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE The BRCA1 gene had the highest mutation frequency in patients with triple-negative breast cancer (TNBC), which was 9.6% (n = 42), while the BRCA2 gene had the highest mutation frequency in patients with Luminal, which was 3.2% (n = 58). 30720863 2019
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE The frequencies of the BRCA2 mutations were not significantly different between patients with triple-negative breast cancer and those with non-triple-negative breast cancer (1.8% vs. 3.8%, p = 0.46). 30968603 2019
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE Mutations in BRCA1 and BRCA2 genes account for around 2-3% of breast cancer events and more than 10% of triple negative breast cancers. 29582690 2018
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers. 28929593 2018
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 Biomarker disease BEFREE Recent advances in our understanding of homologous recombination (HR) deficiency, including FDA approval of PARP inhibitor olaparib for BRCA1 or BRCA2 mutation carriers, and host anti-tumor immunity in TNBC offer potential for new and biomarker-driven approaches to treat TNBC. 29736741 2018
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE A total of 127 women with TNBC (15.8%) were gBRCA mutation carriers (BRCA1: n = 118, 14.7%; BRCA2: n = 9, 1.1%). 29514593 2018
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE Patients and Methods Germline DNA was sequenced to identify mutations in BRCA1 and BRCA2 in 493 patients with TNBC from the GeparQuinto study. 29791287 2018
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE To determine whether BRCA1 and BRCA2 germline mutation status affects therapy response in patients with TNBC. 28715532 2017
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE BRCA1 and BRCA2 germline mutations account for up to 30% of inheritable breast cancers and are the most commonly assessed mutations in patients presenting with early-onset breast cancer, triple-negative breast cancer, bilateral breast cancer, and a family history of breast cancer. 28423155 2017
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 Biomarker disease BEFREE Although PARP inhibitors represent a promising treatment in TNBC with BRCA1/BRCA2 mutations, there is great interest in identifying drug combinations that can extend the use of PARP inhibitors to a majority of TNBC patients with wild-type BRCA1/BRCA2 Here we explored whether mTOR inhibitors, through modulating homologous recombination (HR) repair, would provide therapeutic benefit in combination with PARP inhibitors in preclinical models of BRCA-proficient TNBC. 26546619 2016
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE Seven of the 9 BRCA1 mutations and the single FANCI mutation were in the TNBC group; 9 of the 11 BRCA2, 1 of the 2 RAD50 as well as BRIP1, MSH2, MUTYH, and RAD51C mutations were in the hormone receptor (HR)(+)Her2(-) group, and the other RAD50, ATM, and TP53 mutations were in the HR(+)Her2(+) group. 26824983 2016
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 Biomarker disease BEFREE We assessed the frequency of mutations in 17 predisposition genes, including BRCA1 and BRCA2, in a large cohort of patients with triple-negative breast cancer (TNBC) unselected for family history of breast or ovarian cancer to determine the utility of germline genetic testing for those with TNBC. 25452441 2015
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE At the most recent (5-year) follow-up, the patient was alive with good quality of life and no evidence of metastases.This finding suggests that BPC therapy might be considered a good therapeutic option for the treatment of metastatic TNBC in a woman with a BRCA2 germline mutation. 26496295 2015
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE Mutations in BRCA1 and BRCA2 or another breast cancer gene occur in one in four African American breast cancer patients with early onset disease, family history of breast or ovarian cancer, or TNBC. 25428789 2015
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 AlteredExpression disease BEFREE Knocking down of BRCA1 or BRCA2 in TNBC cells with BRCA1 allelic loss by RNA interference significantly enhanced AZD2281-induced growth inhibition and induced significant autophagy that was associated with mitophagy in cells with BRCA mutations. 25975349 2015
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE A BRCA mutation was detected in 44 of 190 patients with triple-negative breast cancer (23 %). 25716084 2015
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE Young patients, patients with triple-negative breast cancer (TNBC), and those who harbor a deleterious mutation in BRCA1 or BRCA2 are frequently considered to be at highest risk of local failure, leading to speculation that more-aggressive surgical treatment is warranted in these patients. 26432360 2015
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. 25682074 2015
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients. 24894343 2014
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE PALB2 has been shown to be a moderate-penetrance breast cancer susceptibility gene and is involved in the same DNA damage repair pathway as BRCA1 and BRCA2; this raises the possibility that germline PALB2 mutations may be involved in the pathogenesis of TNBCs. 23824750 2014
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE Here, we analyze the feasibility of using limited family structure and TNBC as predictors of BRCA mutation status in early-onset breast cancer patients attending genetic counseling units. 25342642 2014
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE While sequencing of a select number of triple negative, basal-like FMAs and testing for loss of heterozygosity of BRCA1 and BRCA2 did not identify mutations similar to those described in human TNBC, further in-depth evaluation is required to elucidate a potential role of BRCA in the tumorigenesis of triple negative, basal-like FMAs. 24004841 2013
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.100 GeneticVariation disease BEFREE We found that among women diagnosed with breast cancer aged 36 to 50 years but with no family history of breast or ovarian cancer, the prevalence of BRCA1 and BRCA2 mutations was similar in TNBC (8.5%) and non-TNBC patients (6.7%). 23116406 2012